Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026670 | 0.86 | FFAR1 (0.48) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL7303734 | 0.86 | PPARA (0.51) | ALDH1A1NPC1RAB9APPARAL3MBTL1 | |
| SCHEMBL7350612 | 0.85 | BLM (0.43) | FFAR1ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL8101750 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6915551 | 0.82 | FFAR1 (0.48) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL8026606 | 0.78 | HSD17B10 (0.47) | ALDH1A1MAPK1NPC1RAB9AMEN1 | |
| SCHEMBL9141295 | 0.77 | FFAR1 (0.52) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL98007 | 0.77 | ALDH1A1 (0.48) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL98008 | 0.77 | ALDH1A1 (0.48) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL1527726 | 0.77 | ALDH1A1 (0.48) | FFAR1MTNR1AMTNR1BALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698292-A | Aptamers binding to thiamine analogs and derivatives | 梅里特斯英国第二有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | FFAR1 142/4885MTNR1A 471/4885MTNR1B 519/4885 |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | FFAR1 142/4885MTNR1A 471/4885MTNR1B 519/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | FFAR1 390/4885MTNR1A 319/4885MTNR1B 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.